Global Huntington's Disease Treatment Market to Reach US$ 2,248.1 Million by 2032, Stimulated by Rising Prevalence of Genetic Disorders

August 25, 2023 | Healthcare

According to the latest report by IMARC Group, titled “Huntington's Disease Treatment Market Report by Type (Symptomatic Treatment, Disease-modifying Therapies), Drug Type (Approved Drugs, Off-label Drugs), Age (Below 50 Years, Above 50 Years), Distribution Channel (Drug Stores and Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, and Others), and Region 2024-2032,” the global Huntington's disease treatment market size reached US$ 491.1 Million in 2023. Huntington's disease is a hereditary, neurodegenerative disorder that affects the nerve cells of the brain and leads to a decline in motor control, cognition, and emotional stability. It is caused by a mutation in the HTT gene, which leads to the production of a huntingtin faulty protein that accumulates in the brain and causes damage to nerve cells over time. It can be treated by prescribed medications that help control movement-related symptoms, such as chorea and rigidity. Moreover, researchers are seeking to understand its mechanisms better and develop more effective therapeutic interventions.

Global Huntington's Disease Treatment Market Trends:

The surging prevalence of genetic disorders represents one of the major factors driving the demand for Huntington's disease treatment around the world. Moreover, the rising awareness about the disease among both medical professionals and people is augmenting the market growth. In addition, the growing improvements in diagnostic techniques that allow for earlier detection and intervention, which emphasizes the need for effective treatments are influencing the market positively. Furthermore, the increasing elderly population, which is more prone to develop neurodegenerative disorders, is contributing to the market growth. Besides this, growth in the healthcare infrastructure, rising number of clinical trials, and the growing preferences for personalized medicines are creating a positive outlook for the market. Looking forward, the market value is projected to reach US$ 2,248.1 Million by 2032, expanding at a CAGR of 17.9% during 2024-2032.

Market Summary:

Based on the type, symptomatic treatment currently dominates the market, followed by disease-modifying therapies.
On the basis of the drug type, approved drugs (Tetrabenazine and Deutetrabenazine) represent the largest segment, followed by the off-label drugs.
Based on the age, the below 50 years segment holds the largest market share, followed by above 50 years.
On the basis of the distribution channel, the market has been segmented into drug stores and retail pharmacies, hospital pharmacies, and online pharmacies. At present, drug stores and retail pharmacies account for the largest market share.
Based on the end users, the market has been classified into hospitals, homecare, specialty clinics, and others.
Region-wise, the market has been categorized into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. Amongst these, North America enjoys the leading position in the market.
The competitive landscape of the market has also been examined, with some of the key players being AOP Health, Apotex Inc., Dr. Reddy’s Laboratories Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals PLC, Lupin Limited, Prilenia Therapeutics, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Vaccinex Inc.

Report Scope:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Million
Types Covered	Symptomatic Treatment, Disease-modifying Therapies
Drug Types Covered	• Approved Drugs: Tetrabenazine, Deutetrabenazine • Off-label Drugs
Ages Covered	Below 50 Years, Above 50 Years
Distribution Channels Covered	Drug Stores and Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
End Users Covered	Hospitals, Homecare, Specialty Clinics, Others
Regions Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	AOP Health, Apotex Inc., Dr. Reddy’s Laboratories Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals PLC, Lupin Limited, Prilenia Therapeutics, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Vaccinex Inc. etc.
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Huntington's Disease Treatment Market to Reach US$ 2,248.1 Million by 2032, Stimulated by Rising Prevalence of Genetic Disorders

Purchase options

Single User License ~~$3899~~ $2999
Five User License ~~$4899~~ $3999
Corporate User License ~~$5899~~ $4999

Inquire Before Buying

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.